The Middle East and Africa myasthenia gravis treatment market is anticipated to witness significant growth in the future due to rise in prevalence of the disease. Myasthenia Gravis (MG) is a chronic autoimmune disorder, characterized by fatigued skeletal muscles, resulting in partial or complete paralysis.
The Middle East and Africa myasthenia gravis treatment market is driven by various factors, including rise in awareness among individuals regarding the diseases, surge in disposable income of individuals, increase in efforts by government & key players to support individuals suffering from the disease, and boost in number of medical practitioners & healthcare professionals. The Governments of Middle East and Africa are taking initiatives to increase awareness among citizens regarding myasthenia gravis & various treatments available for it. This is anticipated to augment the market growth during the forecast period.
However, the major restraints of the Middle East and Africa myasthenia gravis treatment market are high costs associated with its medications, limited availability of certain medicines, and their side effects. On the contrary, rise in investments in R&D activities by governments and leading market players is projected to boost the market in the upcoming years. In addition, continuous advancements in the healthcare sector, which captures and compiles the data regarding prevalence of the disease, are projected to provide various lucrative opportunities to key market players in the Middle East and Africa. Furthermore, the Middle East and Africa myasthenia gravis treatment market is anticipated to augment in the future owing to developments in healthcare infrastructure and increase in access to healthcare among the population.
The Middle East and Africa myasthenia gravis treatment market is segmented by drug class, age group, and distribution channel. On the basis of drug class, the market is divided into monoclonal antibodies, intravenous immunoglobulin, and others. Depending on age group, the market is bifurcated into below 55 years and above 55 years. As per distribution channel, the market is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers.
Governments of the Middle East and Africa are expected to play considerable role in the development of the market. They are working to increase investments in R&D and boost the occurrence of clinical trials to develop cost-effective yet potent treatment for myasthenia gravis. In addition, key players in the market aim to tap collaboration opportunities and expand their geographical reach. Furthermore, the market players are striving to garner high market share and gain one-upmanship in the market.
Novartis AG, AbbVie Inc., Biogen, AstraZeneca, GlaxoSmithKline PLC, Hoffmann-La Roche Ltd., Merck & Co., Inc., CSL Behring LLC, Baxter International, and Bristol-Myers Squibb Company are some of the key players operating in the Middle East and Africa myasthenia gravis treatment market.
The Middle East and Africa myasthenia gravis treatment market is driven by various factors, including rise in awareness among individuals regarding the diseases, surge in disposable income of individuals, increase in efforts by government & key players to support individuals suffering from the disease, and boost in number of medical practitioners & healthcare professionals. The Governments of Middle East and Africa are taking initiatives to increase awareness among citizens regarding myasthenia gravis & various treatments available for it. This is anticipated to augment the market growth during the forecast period.
However, the major restraints of the Middle East and Africa myasthenia gravis treatment market are high costs associated with its medications, limited availability of certain medicines, and their side effects. On the contrary, rise in investments in R&D activities by governments and leading market players is projected to boost the market in the upcoming years. In addition, continuous advancements in the healthcare sector, which captures and compiles the data regarding prevalence of the disease, are projected to provide various lucrative opportunities to key market players in the Middle East and Africa. Furthermore, the Middle East and Africa myasthenia gravis treatment market is anticipated to augment in the future owing to developments in healthcare infrastructure and increase in access to healthcare among the population.
The Middle East and Africa myasthenia gravis treatment market is segmented by drug class, age group, and distribution channel. On the basis of drug class, the market is divided into monoclonal antibodies, intravenous immunoglobulin, and others. Depending on age group, the market is bifurcated into below 55 years and above 55 years. As per distribution channel, the market is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers.
Governments of the Middle East and Africa are expected to play considerable role in the development of the market. They are working to increase investments in R&D and boost the occurrence of clinical trials to develop cost-effective yet potent treatment for myasthenia gravis. In addition, key players in the market aim to tap collaboration opportunities and expand their geographical reach. Furthermore, the market players are striving to garner high market share and gain one-upmanship in the market.
Novartis AG, AbbVie Inc., Biogen, AstraZeneca, GlaxoSmithKline PLC, Hoffmann-La Roche Ltd., Merck & Co., Inc., CSL Behring LLC, Baxter International, and Bristol-Myers Squibb Company are some of the key players operating in the Middle East and Africa myasthenia gravis treatment market.
Key Benefits For Stakeholders
- Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
- Analyze the key strategies adopted by major market players in Middle East and Africa Myasthenia Gravis Treatment Market.
- Assess and rank the top factors that are expected to affect the growth of Middle East and Africa Myasthenia Gravis Treatment Market.
- Top Player positioning provides a clear understanding of the present position of market players.
- Identify key investment pockets for various offerings in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Product Benchmarking / Product specification and applications
- Upcoming/New Entrant by Regions
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Age group
- Below 55 years
- Above 55 years
By Drug class
- Monoclonal antibodies
- Intravenous immunoglobulin
- Others
By Distribution channel
- Hospital pharmacies
- Drug store and retail pharmacies
- Online providers
- Key Market Players
- Novartis AG
- AbbVie Inc.
- Biogen
- AstraZeneca
- Novartis AG
- GlaxoSmithKline PLC
- Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- CSL Behring LLC
- Baxter International
- Bristol-Myers Squibb Company
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS
CHAPTER 5: MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP
CHAPTER 6: MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: COMPETITIVE LANDSCAPE
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Novartis AG
- AbbVie Inc.
- Biogen
- AstraZeneca
- Novartis AG
- GlaxoSmithKline PLC
- Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- CSL Behring LLC
- Baxter International
- Bristol-Myers Squibb Company
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
